Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases

NCT04610684 is registered in ClinicalTrials.gov with Jeffrey Clarke as lead sponsor.

NCT NCT04610684
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04610684 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases
Lead sponsor
Jeffrey Clarke
Phase
Phase 2
Overall status
Terminated
Start date
January 5, 2021
Completion date
September 20, 2022
Enrollment
3 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

brain metastases, small-cell lung cancer